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For years, antifungal drug resistance in Candida species has been associated to the
expression of ATP-Binding Cassette (ABC) multidrug transporters. More recently, a few
drug efflux pumps from the Drug:H+ Antiporter (DHA) family have also been shown to
play a role in this process, although to date only the Candida albicans Mdr1 transporter
has been demonstrated to be relevant in the clinical acquisition of antifungal drug
resistance. This work provides evidence to suggest the involvement of the C. glabrata
DHA transporters CgAqr1, CgQdr2, CgTpo1_1, and CgTpo3 in the clinical acquisition
of clotrimazole drug resistance. A screening for azole drug resistance in 138 C. glabrata
clinical isolates, from patients attending two major Hospitals in Portugal, was performed.
Based on this screening, 10 clotrimazole susceptible and 10 clotrimazole resistant
isolates were selected for further analysis. The transcript levels of CgAQR1, CgQDR2,
CgTPO1_1, and CgTPO3 were found to be significantly up-regulated in resistant isolates
when compared to the susceptible ones, with a level of correlation that was found to be
similar to that of CgCDR2, an ABC gene known to be involved in the clinical acquisition
of resistance. As a proof-of-concept experiment, the CgTPO3 gene was deleted in an
azole resistant C. glabrata isolate, exhibiting high levels of expression of this gene.
The deletion of CgTPO3 in this isolate was found to lead to decreased resistance
to clotrimazole and fluconazole, and increased accumulation of azole drugs, thus
suggesting the involvement of this transporter in the manifestation of azole resistance.
Keywords: azole drug resistance, clotrimazole, fluconazole, drug:H+ antiporters, clinical isolates, Candida
glabrata
INTRODUCTION
In recent years, Candida glabrata has become the second most common cause of mucosal and
invasive candidosis, only surpassed by C. albicans (Vermitsky and Edlind, 2004; Rodrigues et al.,
2014; Yapar, 2014). C. glabrata is, indeed, responsible for 15–20% of all known Candida infections,
with its relative incidence increasing every year (Roetzer et al., 2011). The extensive use of
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antifungal drugs both as treatment and prophylaxis has led to a
huge increase in the number of intrinsically resistant infections
with fungal pathogens. The frequency and relative high mortality
levels of these infections are generally attributed to the capacity
of these pathogenic yeasts to efficiently develop multiple drug
resistance (MDR; Vermitsky and Edlind, 2004; Sanguinetti et al.,
2005; Rezaei et al., 2009).
Azole antifungals, including fluconazole (FLC) and
clotrimazole (CLT), are commonly used in clinical practice
(Pina-Vaz et al., 2001; Vermitsky and Edlind, 2004). One of the
most frequent azole formulations used for treatment of fungal
mucocutaneous infections, such as vaginal and oropharyngeal
candidiasis, is the imidazole clotrimazole (Crowley and
Gallagher, 2014). Fluconazole, on the other hand, has been
extensively used in prophylaxis and in the therapy of candidosis
in organ and bone marrow transplant recipients, patients
undergoing chemotherapy and AIDS patients. It has been shown
that prolonged fluconazole exposure may favor the up rise of
C. glabrata infections (Abbes et al., 2013; Papon et al., 2013). Both
drugs act by inhibiting lanosterol 14α-demethylase, product of
the ERG11 gene (Vermitsky and Edlind, 2004), a key enzyme
in ergosterol biosynthesis. However, a disturbing percentage
of the C. glabrata clinical isolates have been shown to display
azole resistance, unlike what has been observed for most other
Candida species (Sanguinetti et al., 2005). For example, in a study
involving 33 C. glabrata isolates, 20 were found to be resistant to
fluconazole and ketoconazole (Sanguinetti et al., 2005).
There are mainly three described mechanisms of azole
resistance in Candida spp.: (i) increased production of the
azole target enzyme Erg11, (ii) point mutations in the same
enzyme, affecting drug binding, and (iii) drug eﬄux mediated
by Cdr1 and Cdr2, multidrug eﬄux pumps belonging to the
ATP-binding cassette superfamily (ABC), or, in C. albicans, by
Mdr1, a major facilitator superfamily (MFS) transporter (Henry
et al., 2000; Silva et al., 2011). Additionally, point mutations in
ERG3, encoding for 15,6-desaturase, impairing enzyme activity
have been described to confer azole resistance (Martel et al.,
2010). Recent analysis, however, of the mechanisms underlying
the acquisition of azole drug resistance in C. glabrata suggest that
the expression level or amino acid substitutions of the ERG11
gene do not seem to correlate with the azole resistance levels in
this fungal pathogen (Sanguinetti et al., 2005; Szweda et al., 2015).
In C. glabrata, azole resistance has also been found to be
closely related with the action of the ABC superfamily multidrug
transporters CgCdr1 and CgCdr2 (Sanguinetti et al., 2005; Silva
et al., 2011). MDR transporters belonging to the MFS have
recently been associated to this phenomenon (Costa et al.,
2013a,b, 2014b). CgAqr1 has been shown to confer resistance
to flucytosine and, to a lower extent, clotrimazole, (Costa
et al., 2013a), while CgQdr2 was found to confer resistance
to the imidazoles clotrimazole, thioconazole, miconazole, and
ketoconazole (Costa et al., 2013b), and CgTpo1_1, CgTpo1_2
and CgTpo3 were shown to confer resistance to imidazoles
as well as to the triazoles itraconazole and fluconazole (Costa
et al., 2014b; Pais et al., 2016). As for the remaining five
predicted drug transporters of the same family in C. glabrata,
only CgFlr1 was characterized (Costa et al., 2014a), but shown
not to be involved in azole drug resistance (Chen et al., 2007).
However, their clinical relevance had yet to be assessed as, for
instance, in C. albicans, Mdr1 has been consistently found to be
overexpressed in fluconazole resistant isolates (Wirsching et al.,
2000a,b), but that was not the case of C. albicans Flu1 transporter.
In this study, the clinical relevance of the five DHA
transporters previously found to be involved in azole resistance
in C. glabrata (CgAqr1, CgQdr2, CgTpo1_1, CgTpo1_2, and
CgTpo3) was evaluated. A collection of clinical isolates was
characterized in what concerns susceptibility to two drugs,
representative of azole antifungal drug families: fluconazole,
a triazole used in the treatment and prophylaxis of invasive
candidiasis, and clotrimazole, an imidazole used to treat
mucosal infections. In strains selected for displaying high
or low clotrimazole MIC values the expression of CgAQR1,
CgQDR2, CgTPO1_1, CgTPO1_2, and CgTPO3 was analyzed,
and compared to that of CgCDR1 and CgCDR2, used as
positive controls. Furthermore, one of the DHA genes under
analysis, CgTPO3 was deleted in an azole resistant clinical isolate,
exhibiting high levels of CgTPO3 expression, and its effect on
azole susceptibility was analyzed.
MATERIALS AND METHODS
Candida glabrata Strains and Growth
Media
Two collections of clinical strains, comprising 75 isolates
collected from patients admitted to Hospital of Santa Maria
(HSM), Lisboa, and 63 isolates harvested from patients attending
Centro Hospitalar São João (CHSJ) (Costa-de-Oliveira et al.,
2008; Faria-Ramos et al., 2014), Porto, were used in this study
(Supplementary Table S1). Cells were batch-cultured at 30◦C
with orbital agitation (250 rpm) in YPD growth media, with
the following composition (per liter): 20 g glucose (Merck),
20 g yeast extract (Difco) and 10 g peptone (Difco). For some
of the experiments basal medium (BM) was used with the
following composition (per liter): 1.7 g yeast nitrogen base
without amino acids or NH4+ (Difco), 20 g glucose (Merck)
and 2.65 g (NH4)2SO4 (Merck). Solid media contained 20 g/L
agar (Iberagar) besides the ingredients listed above. Fluconazole
(FLC) and Clotrimazole (CLT) were obtained from Sigma,
prepared in dimethyl sulfoxide (Sigma), frozen at −80◦C until
use. The antifungal solutions used for the MIC determination
were diluted with RPMI 1640 medium (Sigma) and buffered
to pH 7.0 with 0.165 M morpholinepropanesulfonic acid buffer
(Sigma).
Susceptibility Testing of C. glabrata
Isolates
The Minimal Inhibitory Concentration (MIC) of each antifungal
drug was determined according to the M27-S4 protocol of the
Clinical and Laboratory Standards Institute (CLSI) (CLSI, 2008,
2012), for the isolates obtained from Centro Hospitalar São João,
and by the EUCAST definitive document EDef 7.2 (Rodríguez-
Tudela et al., 2003), for the isolates collected at Hospital of Santa
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Maria. EUCAST and CLSI methods have been shown to provide
similar results in terms of MIC determinations (Cuenca-Estrella
et al., 2002; Rodriguez-Tudela et al., 2007; Pfaller et al., 2011).
The MICs were determined after 48 h of incubation for both
FLC and CLT. The susceptibility breakpoints for FLC were those
proposed by the CLSI M27-S4 document. For FLC, the MIC
value thresholds to consider a strain susceptible-dose dependent
or resistant were ≤32 µg/ml or ≥64 µg/ml, (CLSI, 2008, 2012).
In the case of CLT there are no established breakpoints. The
considered MIC value thresholds – for susceptibility ≤0.5 µg/ml
and for resistance ≥1 µg/ml – were according to previously
published standards for C. albicans (Pelletier et al., 2000). The
C. glabrata CBS138 type strain was used for quality control of
antifungal susceptibility testing.
The susceptibility of the clinical isolate 51800, and of the
derived 51800_1tpo3 mutant, to CLT and FLC was compared
based on MIC determination, as described above, and on
growth in solid medium. C. glabrata cells were grown in BM
medium until mid-exponential phase (OD600nm = 0.4 ± 0.02)
and diluted in sterile water to obtain suspensions with
OD600nm = 0.05 ± 0.005. These cell suspensions and subsequent
dilutions (1:5 and 1:25) were applied as 4µl spots onto the surface
of agarized BM medium, supplemented with 20 and 24 mg/l of
CLT and 475 and 500 mg/L of FLC.
Gene Expression Analysis
Ten CLT susceptible and 10 CLT resistant isolates were selected
(Table 3) to assess the transcript levels of the MFS-MDR genes
CgAQR1, CgQDR2, CgTPO1_1, CgTPO1_2, and CgTPO3 and of
the ABC genes CgCDR1 and CgCDR2 by quantitative real-time
PCR (qRT-PCR). Total-RNA samples were obtained from cell
suspensions harvested upon reaching an OD600nm = 0.8 ± 0.08
(mid-exponential-phase cells). cDNA for real-time reverse
transcription-PCR was synthesized from total-RNA samples
by using the MultiScribeTM reverse transcriptase kit (Applied
Biosystems) and the 7500 RT-PCR thermal cycler block (Applied
Biosystems). The quantity of cDNA for subsequent reactions
was kept at ca. 10 ng. The subsequent RT-PCR step was carried
out using SYBR green reagents. Primers for the amplification of
the five genes and CgACT1 were designed using Primer Express
software (Applied Biosystems) and are summarized in Table 1.
The RT-PCR was carried out using a thermal cycler block (7500
real-time PCR system; Applied Biosystems). Default parameters
established by the manufacturer were used, and fluorescence was
detected by the instrument and recorded in an amplification plot
(7500 System SDS software; Applied Biosystems). The CgACT1
mRNA level was used as an internal control. The relative values
obtained for the clotrimazole-susceptible isolate exhibiting the
lower gene expression level were set as 1 and the remaining
values are presented relative to that control. Statistical analysis
of the results was performed using ANOVA, and differences were
considered statistically significant for p-values< 0.05.
Disruption of CgTPO3
The deletion of gene CgTPO3 was carried out in the parental
strain 51800 using the method described by Reuss et al.
(2004). The gene to be deleted was replaced by a SAT1 flipper
cassette by homologous recombination using primers 5′ –
CCCTCCAATCCAGATTGACGCAGTGGGGTTATAGGTTAC
TGAGGTGTTTCTATATATACAATGGACGGTGGTATGTTT-
3′ and 5′ –ATATATTATGATTCAATGAGAAGTACATTAGATG
TAGGAGGTGGAAGTAAGGGGAGTTGTTTAGGCGTCATCC
TGTGCTC- 3′. The underlined region of the primers has
homology with the gene to be amplified while the italic region
has homology with the SAT1 flipper cassette encoding sequence.
The pA83 plasmid including CgSAT1 was used as a template,
and transformation was performed using the Alkali-Cation
Yeast Transformation Kit (MP Biomedicals). Appropriate
PCR products were identified and verified by PCR using the
following pairs of primers: 5′ –CAGAATTTGAACCTTCGGTG-
3′ which is assigned to the inside of the open reading frame
of CgTPO3, and 5′ –GCCCAGATAACAACACAAGTCC- 3′
which is specific for the cassette DNA. No PCR products were
identified from the template DNA of the mutant, while a clear
PCR product was identified from the template DNA of the
parental strain.
[3H]-Clotrimazole Transport Assays
[3H]-clotrimazole accumulation assays were carried out
as described before (Costa et al., 2013b). To estimate its
accumulation (Intracellular/Extracellular) in yeast cells, they
were grown in BM medium till mid-exponential phase,
harvested, washed and resuspended in BM medium, to
obtain cell suspensions with an OD600nm = 5.0 ± 0.1,
equivalent to approximately 2.2 mg (dry weight) ml−1. After
5 min thermostatization at 30◦C, 0.1 µM of 3H-clotrimazole
(American Radiolabeled Chemicals; 1 mCi/ml) and 30 mg/l
of unlabeled clotrimazole were added to the suspension. The
accumulation of 3H-clotrimazole, followed for 30 min, was
followed by filtering 200 µl of cell suspension, at adequate
time intervals, through glass microfiber filters (Whatman
GF/C). The filters were washed with ice-cold TM buffer and the
radioactivity measured in a Beckman LS 5000TD scintillation
TABLE 1 | Pairs of primers designed for RT-PCR.
Gene Primer Sequence
CgACT1 Forward 5′ -AGAGCCGTCTTCCCTTCCAT- 3′
Reverse 5′ -TTGACCCATACCGACCATGA- 3′
CgAQR1 Forward 5′ -GCTGATAAGTTCGGCCGTAGA -3′
Reverse 5′ -AATGGAGGCAACCACGTAGATC- 3′
CgCDR1 Forward 5′ -GCTTGCCCGCACATTGA -3′
Reverse 5′ -CCTCAGGCAGAGTGTGTTCTTTC- 3′
CgCDR2 Forward 5′ -GCCATGGTACCTGCATCGAT- 3′
Reverse 5′ -CCGAGGAATAGCAAAACCAGTATAC- 3′
CgQDR2 Forward 5′ -TCACTGCATAGTTTCATATCGGACTA- 3′
Reverse 5′ -CAACTTCAGATAGATCAGGACCATCA- 3′
CgTPO1_1 Forward 5′ -CGCTGCTTCCCCAGTTATCT- 3′
Reverse 5′ -CTAGCACACCACGTCTACCGTAA- 3′
CgTPO1_2 Forward 5′ -AGGACCCGCTCTATCGAAAAA- 3′
Reverse 5′ -GCTGCGACTGCTGACTCAAC- 3′
CgTPO3 Forward 5′ -TGCCGATATGTTCCCAAGTGA- 3′
Reverse 5′ -TGGAGCGAAAGCGAAGAAAG- 3′
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counter. Extracellular concentration of 3H-clotrimazole
was estimated, by radioactivity assessment of 50 µl of the
supernatant. To calculate the intracellular concentration of
each radiolabeled compound, the internal cell volume (Vi) of
the exponential cells, grown in the absence of drug and used
for accumulation assays, was considered constant and equal
to 2.5 µl (mg dry weight)−1 (Rosa and Sa-Correia, 1996).
Statistical analysis of the results was performed using ANOVA,
and differences were considered statistically significant for
p-values< 0.05.
RESULTS
Susceptibility Profiles of C. glabrata
Isolates Toward Clotrimazole and
Fluconazole
In this study, 138 C. glabrata isolates, coming from two major
Portuguese hospitals, were screened for azole drug resistance.
The majority of these isolates were harvested from women (64%)
and from individuals over 65 years (54%). The most common
niches from which they were recovered were urine (31%), blood
culture (19%), mucus (16%) and in lower number from vaginal
smear, bronchoalveolar lavage, pus, feces, and peritoneal fluid
(Supplementary Table S1). FLC resistance levels for 29% of this
collection, corresponding to the O and OL isolates harvested
from Centro Hospitalar S. João (CHSJ), had been previously
obtained (Costa-de-Oliveira et al., 2008, 2011; Faria-Ramos et al.,
2014).
Susceptibility profiles against the CLT and FLC for all
C. glabrata isolates are summarized in Table 2 (see details in
Supplementary Table S1). Regarding the MIC50 values, most
isolates (93.5%) were found to be susceptible-dose dependent
to FLC, while 9 (6.5%) were found to be resistant to FLC.
Additionally, most isolates (64.5%) were found to be resistant to
CLT. Interestingly, 48 isolates (34.78%) were found to be resistant
to CLT and, at the same time, susceptible-dose dependent to
FLC. The opposite, however, was not observed for any of the
tested strains. In what concerns CLT, 53.3% of the isolates
coming from Hospital of Santa Maria (HSM) were found to
be resistant, while isolates harvested in CHSJ had a much
higher incidence of clotrimazole-resistance (77.8%). Fluconazole-
resistant isolates had a higher incidence in HSM (10.7% vs.
1.6%). Interestingly, using a Spearman test (Spearman coefficient:
0.27) a significant correlation was found to exist between the
increase in CLT MIC levels and the FLC MIC levels, when
considering the full 138 clinical isolates (Figure 1). The level of
correlation, however, is relatively low, accounting for a number of
isolates exhibiting CLT resistance and very low FLC MIC values,
and suggesting that there may be differences in the molecular
mechanisms of acquisition of resistance to these related azole
drugs.
The percentage of clotrimazole- and fluconazole- resistant
isolates was found to be similar in both superficial infections and
blood infections with 63% of resistant isolates in blood infections
vs. 64.9% of resistant isolates in superficial infections for
clotrimazole, and 7.4% resistant isolates in blood infections
and 6.3% isolates resistant in superficial infections for
fluconazole.
FIGURE 1 | Correlation between the fluconazole and clotrimazole
MIC50 values determined for the collection of 138 Candida glabrata
clinical isolates. A trendline obtained by linear regression of the correlation
values is also displayed. A significant correlation using a Spearman test (0.27)
was found to exist between clotrimazole (CLT) and fluconazole (FLC) datasets.
TABLE 2 | Susceptibility profiles of the 138 Candida glabrata isolates to the widely used antifungal drugs clotrimazole and fluconazole by the reference
broth microdilution method∗.
Species Antifungal MIC range (Mg/mL) Origin (no. of isolates) % of isolates
S SDD R
Candida glabrata Fluconazole 0.125–>64 Both hospitals (138) 93.5 6.5
HSM (75) 89.3 10.7
CHSJ (63) 98.4 1.6
Clotrimazole 0.03125-8 Both hospitals (138) 35.5 64.5
HSM (75) 46.7 53.3
CHSJ (63) 22.2 77.8
∗Performed as described by Eucast document EDef 7.2 (Rodríguez-Tudela et al., 2003) or CLSI document M27-A3 (CLSI, 2008, 2012).
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Clotrimazole Resistance in C. glabrata
Clinical Isolates Correlates with the
Expression of the DHA Genes CgAQR1,
CgQDR2, CgTPO1_1, and CgTPO3
In order to evaluate the predicted role of the Drug:H+
Antiporters CgAqr1, CgQdr2, CgTpo1_1, CgTpo1_2, and
CgTpo3 in the clinical acquisition of azole drug resistance
(Costa et al., 2014a), their expression levels in 20 clinical
isolates, 10 exhibiting clotrimazole resistance and 10 exhibiting
clotrimazole susceptibility (Table 3), were assessed. The option
to consider clotrimazole R or S strains for further analysis, and
not fluconazole R/SDD strains, is due to the fact that all of the
drug transporters under analysis in this study confer imidazole
resistance, but only three confer triazole resistance as well.
The chosen isolates were also selected for exhibiting the most
extreme MIC values. The expression levels of the ABC multidrug
eﬄux pump encoding genes CgCDR1 and CgCDR2 was also
determined, for the sake of comparison, as their over-expression
is commonly accepted as a key factor in the clinical acquisition
of azole drug resistance (Miyazaki et al., 1998; Sanglard et al.,
1999).
A much higher variability in terms of the DHA gene
expression was found in the azole-resistant strains, when
compared to the susceptible ones. Despite this variability, the
transcript level of CgAQR1, CgQDR2, CgTPO1_1, and CgTPO3
genes was found to be significantly higher in resistant isolates,
when compared to the susceptible ones, considering more
than 70% of the tested strains (Figures 2A–C,E). In the case
of CgTPO1_2, no statistically significant correlation could be
observed (Figure 2D). As expected (Miyazaki et al., 1998;
Sanglard et al., 1999; Bennett et al., 2004), the expression
of CgCDR1 and CgCDR2 was found to correlate with azole
drug resistance in the clinical isolates (Figure 3). It is
important to notice that, the level of correlation between
the expression of CgCDR2 and azole drug resistance was
found to be similar to that observed for the DHA genes
(p-value < 0.05). Consistent with a more relevant role in
this context, a higher degree of correlation between gene
expression and azole drug resistance was found for CgCDR1
(p-value< 0.01).
CgTPO3 Expression Contributes to Azole
Resistance in a Resistant Clinical Isolate
CgTPO3 had previously been shown to contribute to resistance
to clotrimazole and fluconazole in a laboratorial strain (Costa
et al., 2014b). Given the observation that this gene was found
to be up-regulated in clotrimazole resistant clinical isolates,
when compared to susceptible ones, it seemed important to
assess if its absence could affect azole resistance in clinical
isolates as well. Therefore, this gene was deleted in the azole-
resistant isolate 51800, found to exhibit high levels of CgTPO3
expression. The deletion of this gene in the 51800 isolate was
found to significantly decrease its resistance to clotrimazole and
fluconazole (Figures 4A,B), thus reinforcing the notion that this
transporter contributes to azole resistance in the clinical context.
The MIC50 values of clotrimazole and fluconazole for the 51800
and 51800_1cgtpo3 were further evaluated. MIC50 values were
found to be in all cases higher in the parental 51800 strain (8 and
>128 for clotrimazole and fluconazole, respectively) than for the
derived1cgtpo3 deletion mutant (4 and 64, respectively).
Based on the obtained susceptibility results, it appears clear
that CgTpo3 is a player in clinical drug resistance acquisition,
but is not fully responsible for the resistance to clotrimazole
and fluconazole in the 51800 isolate. Indeed, the expression
of additional multidrug transporter encoding genes in this
strain was found to be quite high, when compared to what
was determined in azole susceptible dose-dependent isolates
(Figure 5). This is particularly the case for the CDR1 and AQR1
genes (Figure 4), highlighting the multifactorial nature of azole
drug resistance acquisition in the clinical setting.
CgTPO3 Mediates 3H-Clotrimazole Efflux
in Clotrimazole-Resistant Isolate 51800
Given this observation and the previous demonstration that
CgTPO3 mediates 3H-clotrimazole eﬄux in C. glabrata (Costa
et al., 2014b), CgTpo3 ability to reduce the accumulation of
TABLE 3 | List of the clotrimazole susceptible and resistant C. glabrata clinical isolates selected for the determination of the expression levels of the
DHA genes CgAQR1, CgQDR2, CgTPO1_1, CgTPO1_2, and CgTPO3, and of the ABC genes CgCDR1 and CgCDR2.
Susceptible isolates MIC value (µg/mL) Resistant isolates MIC value (µg/mL)
CLT FLC CLT FLC
21461 0.0625 4 10774 4 >64
43321 0.03125 4 65147 4 64
48241 0.0625 4 90836 4 32
53351 0.0625 4 94078 4 >64
98495 0.0625 4 51800 8 >64
MC426 0.125 1 O79 8 8
OL090 0.25 8 O155 8 32
MC123 0.5 0.25 MC127 8 0.25
MC125 0.5 0.125 MC165 8 8
MC126 0.5 0.125 MC166 8 16
Information about fluconazole MIC values for these isolates is also provided.
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FIGURE 2 | Transcript levels of (A) CgAQR1, (B) CgQDR2, (C) CgTPO1_1, (D) CgTpo1_2, and (E) CgTPO3 in both susceptible (S) and resistant (R)
C. glabrata clinical isolates. Transcript levels were assessed through quantitative RT-PCR, as described in the section “Materials and Methods.” The obtained
values are the average of at least three independent experiments. The average of the expression values in each group of clinical isolates is represented by a red line
(−). ∗p-value < 0.05.
FIGURE 3 | Transcript levels of (A) CgCDR1 and (B) CgCDR2 in both susceptible (S) and resistant (R) C. glabrata clinical isolates. Transcript levels were
assessed through quantitative RT-PCR, as described in the section “Materials and Methods.” The obtained values are the average of at least three independent
experiments. The average of the expression values in each group of clinical isolates is represented by a red line (−). ∗p-value < 0.05, ∗∗p-value < 0.01.
radiolabeled clotrimazole in the C. glabrata clinical isolate 51800
was evaluated. The accumulation of 3H-labeled clotrimazole
in non-adapted C. glabrata 51800 and 51800_1cgtpo3 cells,
suddenly exposed to the presence of 30 mg/L of cold clotrimazole,
was assessed (Figure 6A). In these conditions, cells devoid of
CgTPO3 accumulate twofold higher levels of 3H-clotrimazole
when compared to the parental strain. Since it is possible that
the observed moderate role played by CgTpo3 in clotrimazole
resistance could result from an indirect effect in the expression
of CgCDR1 or CgCDR2, the effect of CgTPO3 deletion in
the 51800 clinical isolate on the expression of CgCDR1 and
CgCDR2 was assessed. The deletion of CgTPO3 was found to
have only a slight effect on CgCDR2 expression and no effect
on CgCDR1 (Figure 6B). This result strongly suggests that
CgTpo3 activity increases C. glabrata resistance to clotrimazole
in clinical isolates by directly reducing its accumulation inside
the cell.
DISCUSSION
In this work, the participation of five multidrug transporters of
the MFS superfamily in the acquisition of clotrimazole resistance
was evaluated in C. glabrata clinical isolates.
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FIGURE 4 | Comparison of the susceptibility to (A) clotrimazole and (B) fluconazole, at the indicated concentrations displayed by the clinical isolate
51800 and the derived 51800_1cgtpo3 deletion mutant, in BM agar plates by spot assays. Cell suspensions used to prepare the spots were (b) 1:5 and (c)
1:25 of the cell suspension used in (a). The displayed images are representative of at least three independent experiments.
FIGURE 5 | Transcript levels of CgAQR1, CgQDR2, CgTPO1_1,
CgTPO1_2, CgTPO3, CgCDR1, and CgCDR2 in the C. glabrata clinical
isolate 51800, when compared to those determined in the susceptible
isolate exhibiting the lowest level of expression for each of these
genes. Transcript levels were assessed through quantitative RT-PCR, as
described in the section “Materials and Methods.” The obtained values are the
average of at least three independent experiments. Error bars represent the
corresponding standard deviation.
The Drug:H+ Antiporter family is poorly characterized
in pathogenic fungi. For example, in the medically relevant
pathogens C. albicans, C. glabrata, C. parapsilosis, C. lusitaniae,
C. tropicalis, C. guilliermondii, Cryptococcus neoformans, and
Aspergillus fumigatus there are nearly 300 ORFs predicted
to encode DHA transporters, but only less than 15 have
been characterized (Costa et al., 2014a). In C. glabrata, five
transporters, CgAqr1 (Costa et al., 2013a), CgQdr2 (Costa et al.,
2013b), CgTpo1_1, CgTpo1_2 (Pais et al., 2016), and CgTpo3
(Costa et al., 2014b), have been recently functionally analyzed and
shown to be involved in azole drug resistance, with a stronger
effect in the resistance against imidazoles. However, the impact
of these findings in the clinical acquisition of resistance remained
unclear.
In this work, 138 C. glabrata clinical isolates were screened
for clotrimazole and fluconazole resistance. The majority of
the isolates were characterized as susceptible-dose dependent to
fluconazole, while 9 (6.5%) were identified as resistant to this
drug. The relative level of resistant isolates was similar to that
observed in previous studies (Sanguinetti et al., 2005; Faria-
Ramos et al., 2014). On the other hand, most isolates tested
(64.5%) were found to be resistant to clotrimazole. The majority
of the isolates were found to be resistant to clotrimazole and
susceptible-dose dependent to fluconazole. It is important to
point out, however, that the identification of a very high number
of clotrimazole resistant isolates is most likely due to the fact
that the resistance threshold considered was that indicated for
C. albicans (Pelletier et al., 2000), since no clotrimazole MIC
breakpoint or suggested resistance threshold was ever indicated
for C. glabrata (CLSI, 2008, 2012). Based on the fact that the
fluconazole breakpoint is eightfold higher for C. glabrata than
for C. albicans (CLSI, 2012), it appears reasonable to assume that
the clotrimazole breakpoint for C. glabrata will also be higher
than for C. albicans. Considering a similar eightfold difference,
the clotrimazole breakpoint would increase to a MIC of 4, which
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FIGURE 6 | (A) Time course accumulation ratio of [3H]-Clotrimazole in non-adapted cells of the parental strain 51800 () or the mutant strain 51800_∆cgtpo3 (),
during cultivation in BM liquid medium in the presence of 30 mg/L unlabeled clotrimazole. (B) Transcript levels of CgCDR1 (in black) and CgCDR2 (in white) in the
C. glabrata clinical isolate 51800, when compared to those determined in the 51800_∆cgtpo3 derived deletion mutant. Transcript levels were assessed through
quantitative RT-PCR, as described in the section “Materials and Methods.” The obtained values are the average of at least three independent experiments. Error bars
represent the corresponding standard deviations. ∗p-value < 0.05, ∗∗p-value < 0.01.
would still imply that nearly 30% of the clinical isolates in the
studied collection displays resistance toward this azole drug.
Resistance (or susceptibility) to clotrimazole and fluconazole
does not seem to correlate with the body niche from which the
C. glabrata isolates were recovered. Also, the levels of resistance
to both drugs are similar whether the isolates came from blood
cultures or superficial infections. This is particularly interesting,
and unexpected, since fluconazole is more commonly used for the
treatment of systemic infections and clotrimazole of superficial
infections.
Since azoles play such an important role in clinical practice,
the cross-resistance potential between imidazoles and triazoles
was also addressed. Interestingly, 48 isolates (34.78%) resistant to
clotrimazole were found to be, at the same time, susceptible-dose
dependent to fluconazole. In agreement with the observation
that there is a statistically significant correlation between the
increase in CLT MIC levels and the FLC MIC levels, when
considering the full 138 clinical isolates, all isolates identified
as resistant to fluconazole (n = 9), were also found to be
resistant to clotrimazole, when considering CLT resistance for
MIC ≥ 1. This is consistent with the observation by Cross
et al. (2000) that fluconazole-resistant bloodstream isolates of
both C. albicans and C. glabrata obtained from cancer patients
showed simultaneous resistance to clotrimazole and two other
imidazoles: tioconazole and miconazole. These observations
raise questions as to the prophylactic use of fluconazole,
as it may induce not only resistance toward other triazoles
(Pfaller et al., 2004, 2007, 2008), but to the more widely
used imidazoles, compromising the treatment of superficial
infections.
Using the results obtained from the characterization of
the isolate collections referred above, the role of the DHA1
transporters CgAqr1, CgQdr2, CgTpo1_1, CgTpo1_2, and
CgTpo3 in the acquisition of clotrimazole resistance in the
clinical setting was evaluated. The option to consider clotrimazole
R, and not fluconazole R, is due to the fact that all of
the drug transporters under analysis in this study confer
imidazole resistance, but only CgTpo1_1, CgTpo1_2, and
CgTpo3 confer triazole resistance as well. Although it is
true that fluconazole and other triazole antifungals are much
more relevant in the treatment of systemic life-threatening
fungal infections, imidazole antifungals such as clotrimazole
are widely used in skin and mucosal infections, which
are themselves a widespread problem, with high recurrence
rates, and constituting an open door to the development
of bloodstream infections. The expression levels of four out
of five of these genes (CgAQR1, CgQDR2, CgTPO1_1, and
CgTPO3) were shown to directly correlate with the increase
in clotrimazole resistance, being up-regulated significantly in
clotrimazole resistant isolates when compared to susceptible
isolates. Interestingly, the expression of CgQDR2 had been
previously shown to be increased in a clinical isolate exhibiting
a CgPDR1 gain-of function mutation (Caudle et al., 2011).
However, for the remaining DHA genes considered in this
study, this is the first demonstration of up-regulation in
clinical isolates, possibly because, to the best of our knowledge,
there are no other studies focused on the clinical acquisition
of clotrimazole resistance. Although the correlation between
gene expression and clotrimazole resistance was seen to be
higher for CgCDR1, as expected given its more prominent
role in this context (Miyazaki et al., 1998; Sanglard et al.,
1999; Bennett et al., 2004), the expression of the DHA
genes had a correlation level similar to that of CgCDR2.
This is particularly relevant since DHA transporters are
much more poorly characterized than ABC transporters. In
fact, before recent studies characterizing these C. glabrata
DHA transporters, the only MFS transporter described as
being involved in drug resistance was C. albicans Mdr1
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(Cannon et al., 2009; Morschhauser, 2010). The involvement
of this transporter in the clinical acquisition of resistance
was demonstrated by the significant up-regulation of its gene
expression levels in C. albicans clinical isolates resistant to
fluconazole (Sanglard et al., 1995; White, 1997), and by an
increased susceptibility toward this drug upon gene disruption,
proving this transporter to mediate fluconazole resistance in
C. albicans clinical isolates (Wirsching et al., 2000b).
Interestingly, the only gene to which no correlation
could be found between the expression levels and resistance
acquisition was CgTPO1_2. This observation was somewhat
unexpected since its expression was previously observed
to be up-regulated following clotrimazole exposure (Pais
et al., 2016). However, this lack of correlation may be due
to the fact that the expression of this gene occurs in a
transient manner (Pais et al., 2016). Also, the high variability
between CgTPO1_2 expression levels in the resistant isolates,
when compared to the susceptible ones, compromised the
statistical significance associated to the correlation between
the transcript levels in these groups of isolates and their
resistance levels. Indeed it is noteworthy that the average
expression levels of CgTPO1_2 were still found to be
considerably higher among resistant isolates than in susceptible
ones.
Similarly to what had been done before for CaMdr1
(Wirsching et al., 2000b), the relevance of CgTpo3 was further
evaluated through gene deletion in a clinical isolate, selected for
showing a high level of CgTPO3 expression. Used here as a proof-
of-concept, the fact that the deletion of CgTpo3 in this clinical
isolate decreases clotrimazole and fluconazole resistance to azole
drugs demonstrates its importance in the clinical acquisition of
azole drug resistance. It is also interesting to point out that all
the tested azole resistant isolates exhibit increased expression
of several of the ABC and DHA drug transporters. However,
their expression profile varies from strain to strain, suggesting
that several evolution paths have been selected by different
strains leading to the same overall azole resistance phenotype.
Indeed, it appears to be the sum of the action exerted by each
of the up-regulated drug eﬄux pumps, not necessarily their
individual action, that ends up building a fully resistant clinical
isolate.
Altogether, this study highlights the importance of the
DHA transporter family in the acquisition of azole drug
resistance. Significantly, these transporters are widely spread
among pathogenic fungi, but only about 5% of them have been
characterized so far (Costa et al., 2014a).
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